Terms: = Pancreatic cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S AND Treatment
41 results:
1. Feasibility of Co-Targeting her3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a pancreatic cancer Xenograft Model.
Xu T; Schulga A; Konovalova E; Rinne SS; Zhang H; Vorontsova O; Orlova A; Deyev SM; Tolmachev V; Vorobyeva A
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769161
[TBL] [Abstract] [Full Text] [Related]
2. A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.
Salawu A; Hansen AR; Spreafico A; Al-Ezzi E; Webster S; Bedard PL; Doi J; Wang L; Siu LL; Abdul Razak AR
Target Oncol; 2022 May; 17(3):271-281. PubMed ID: 35635640
[TBL] [Abstract] [Full Text] [Related]
3. In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized
Hihara F; Matsumoto H; Yoshimoto M; Masuko T; Endo Y; Igarashi C; Tachibana T; Shinada M; Zhang MR; Kurosawa G; Sugyo A; Tsuji AB; Higashi T; Kurihara H; Ueno M; Yoshii Y
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628616
[TBL] [Abstract] [Full Text] [Related]
4. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the treatment of cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
5. Zenocutuzumab, a HER2xher3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
Schram AM; Odintsov I; Espinosa-Cotton M; Khodos I; Sisso WJ; Mattar MS; Lui AJW; Vojnic M; Shameem SH; Chauhan T; Torrisi J; Ford J; O'Connor MN; Geuijen CAW; Schackmann RCJ; Lammerts van Bueren JJ; Wasserman E; de Stanchina E; O'Reilly EM; Ladanyi M; Drilon A; Somwar R
Cancer Discov; 2022 May; 12(5):1233-1247. PubMed ID: 35135829
[TBL] [Abstract] [Full Text] [Related]
6. The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer.
Umemoto K; Sunakawa Y
Crit Rev Oncol Hematol; 2021 Oct; 166():103465. PubMed ID: 34454058
[TBL] [Abstract] [Full Text] [Related]
7. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract] [Full Text] [Related]
8. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
Khan T; Seddon AM; Dalgleish AG; Khelwatty S; Ioannou N; Mudan S; Modjtahedi H
Oncol Rep; 2020 Dec; 44(6):2581-2594. PubMed ID: 33125153
[TBL] [Abstract] [Full Text] [Related]
9. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract] [Full Text] [Related]
10. The role of ErbB4 in cancer.
Segers VFM; Dugaucquier L; Feyen E; Shakeri H; De Keulenaer GW
Cell Oncol (Dordr); 2020 Jun; 43(3):335-352. PubMed ID: 32219702
[TBL] [Abstract] [Full Text] [Related]
11. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of pancreatic cancer.
Ponz-Sarvise M; Corbo V; Tiriac H; Engle DD; Frese KK; Oni TE; Hwang CI; Öhlund D; Chio IIC; Baker LA; Filippini D; Wright K; Bapiro TE; Huang P; Smith P; Yu KH; Jodrell DI; Park Y; Tuveson DA
Clin Cancer Res; 2019 Nov; 25(22):6742-6755. PubMed ID: 31492749
[TBL] [Abstract] [Full Text] [Related]
12.
Jones MR; Williamson LM; Topham JT; Lee MKC; Goytain A; Ho J; Denroche RE; Jang G; Pleasance E; Shen Y; Karasinska JM; McGhie JP; Gill S; Lim HJ; Moore MJ; Wong HL; Ng T; Yip S; Zhang W; Sadeghi S; Reisle C; Mungall AJ; Mungall KL; Moore RA; Ma Y; Knox JJ; Gallinger S; Laskin J; Marra MA; Schaeffer DF; Jones SJM; Renouf DJ
Clin Cancer Res; 2019 Aug; 25(15):4674-4681. PubMed ID: 31068372
[TBL] [Abstract] [Full Text] [Related]
13. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
Momeny M; Esmaeili F; Hamzehlou S; Yousefi H; Javadikooshesh S; Vahdatirad V; Alishahi Z; Mousavipak SH; Bashash D; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Haddad P; Kordbacheh F; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2019 Aug; 42(4):491-504. PubMed ID: 31025257
[TBL] [Abstract] [Full Text] [Related]
14. Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/erbb3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs.
Lin T; Ren Q; Zuo W; Jia R; Xie L; Lin R; Zhao H; Chen J; Lei Y; Wang P; Dong H; Huang L; Cai J; Peng Y; Yu Z; Tan J; Wang S
J Exp Clin Cancer Res; 2019 Apr; 38(1):150. PubMed ID: 30961642
[TBL] [Abstract] [Full Text] [Related]
15. Functional genomic characterization of a synthetic anti-her3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response.
Turowec JP; Lau EWT; Wang X; Brown KR; Fellouse FA; Jawanda KK; Pan J; Moffat J; Sidhu SS
J Biol Chem; 2019 Jan; 294(4):1396-1409. PubMed ID: 30523157
[TBL] [Abstract] [Full Text] [Related]
16. Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors.
El-Behaedi S; Landsman R; Rudloff M; Kolyvas E; Albalawy R; Zhang X; Bera T; Collins K; Kozlov S; Alewine C
Toxins (Basel); 2018 Oct; 10(11):. PubMed ID: 30384408
[TBL] [Abstract] [Full Text] [Related]
17. Imaging EGFR and her3 through
McKnight BN; Kuda-Wedagedara ANW; Sevak KK; Abdel-Atti D; Wiesend WN; Ku A; Selvakumar D; Carlin SD; Lewis JS; Viola-Villegas NT
Sci Rep; 2018 Jun; 8(1):9043. PubMed ID: 29899472
[TBL] [Abstract] [Full Text] [Related]
18. Response to erbb3-Directed Targeted Therapy in
Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
[No Abstract] [Full Text] [Related]
19. Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-her3 Antibody 9F7-F11 by Increasing Its Binding to her3.
Le Clorennec C; Bazin H; Dubreuil O; Larbouret C; Ogier C; Lazrek Y; Garambois V; Poul MA; Mondon P; Barret JM; Mathis G; Prost JF; Pèlegrin A; Chardès T
Mol Cancer Ther; 2017 Jul; 16(7):1312-1323. PubMed ID: 28507002
[TBL] [Abstract] [Full Text] [Related]
20. In vivo evaluation of a novel format of a bivalent her3-targeting and albumin-binding therapeutic affibody construct.
Bass TZ; Rosestedt M; Mitran B; Frejd FY; Löfblom J; Tolmachev V; Ståhl S; Orlova A
Sci Rep; 2017 Feb; 7():43118. PubMed ID: 28230065
[TBL] [Abstract] [Full Text] [Related]
[Next]
